ZA200400804B - Single dose azithromycin for treating respirator infections. - Google Patents
Single dose azithromycin for treating respirator infections. Download PDFInfo
- Publication number
- ZA200400804B ZA200400804B ZA200400804A ZA200400804A ZA200400804B ZA 200400804 B ZA200400804 B ZA 200400804B ZA 200400804 A ZA200400804 A ZA 200400804A ZA 200400804 A ZA200400804 A ZA 200400804A ZA 200400804 B ZA200400804 B ZA 200400804B
- Authority
- ZA
- South Africa
- Prior art keywords
- dose
- substance
- composition
- azithromycin
- treatment
- Prior art date
Links
- 229960004099 azithromycin Drugs 0.000 title claims description 51
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims description 50
- 208000015181 infectious disease Diseases 0.000 title description 17
- 238000000034 method Methods 0.000 claims description 30
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 21
- 208000022760 infectious otitis media Diseases 0.000 claims description 19
- 230000037396 body weight Effects 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims 23
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000606768 Haemophilus influenzae Species 0.000 description 10
- 244000052769 pathogen Species 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 206010033078 Otitis media Diseases 0.000 description 6
- 241000588655 Moraxella catarrhalis Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 241000197194 Bulla Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000011556 gerbil model Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 1
- 206010008326 Cervicitis gonococcal Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000010439 acute gonococcal cervicitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- SRMPHJKQVUDLQE-KUJJYQHYSA-N azithromycin dihydrate Chemical compound O.O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 SRMPHJKQVUDLQE-KUJJYQHYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000028320 gonococcal cervicitis Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31386701P | 2001-08-21 | 2001-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200400804B true ZA200400804B (en) | 2005-05-03 |
Family
ID=23217490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200400804A ZA200400804B (en) | 2001-08-21 | 2004-01-30 | Single dose azithromycin for treating respirator infections. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20030148964A1 (fr) |
| EP (1) | EP1418924A2 (fr) |
| JP (1) | JP2005501862A (fr) |
| KR (1) | KR20040032942A (fr) |
| AP (1) | AP1729A (fr) |
| BG (1) | BG108537A (fr) |
| BR (1) | BR0211830A (fr) |
| CA (1) | CA2458135A1 (fr) |
| CZ (1) | CZ2004232A3 (fr) |
| EA (1) | EA200400214A1 (fr) |
| EC (1) | ECSP044985A (fr) |
| GE (1) | GEP20063812B (fr) |
| HR (1) | HRP20040163A2 (fr) |
| HU (1) | HUP0401332A2 (fr) |
| IL (1) | IL159585A0 (fr) |
| IS (1) | IS7092A (fr) |
| MA (1) | MA27059A1 (fr) |
| MX (1) | MXPA04001605A (fr) |
| OA (1) | OA12845A (fr) |
| PL (1) | PL367888A1 (fr) |
| SK (1) | SK1012004A3 (fr) |
| TN (1) | TNSN04035A1 (fr) |
| WO (1) | WO2003018031A2 (fr) |
| YU (1) | YU8804A (fr) |
| ZA (1) | ZA200400804B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648473B1 (fr) * | 2003-07-24 | 2009-01-28 | PLIVA HRVATSKA d.o.o. | Dose unique a dissolution rapide d'azithromycine |
| JP2007513139A (ja) | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 安定性の改善した多粒子組成物 |
| RU2331410C2 (ru) | 2003-12-04 | 2008-08-20 | Пфайзер Продактс Инк. | Способ получения фармацевтических мультичастиц |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| CA2838111C (fr) | 2005-12-08 | 2016-01-19 | Insmed Incorporated | Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires et procedes d'utilisation de celles-ci |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US20090005326A1 (en) * | 2007-06-26 | 2009-01-01 | Idexx Laboratories, Inc. | Single dose roxithromycin |
| US20090197956A1 (en) * | 2008-02-04 | 2009-08-06 | Arbor Pharmaceuticals, Inc. | Treatment of acute otitis media with xylitol and n-acetylcysteine |
| WO2009114810A2 (fr) * | 2008-03-14 | 2009-09-17 | The Florida International Uinversity Board Of Trustees | Utilisation d'ellagitannines comme inhibiteurs de la détection du quorum bactérien |
| WO2012170356A1 (fr) | 2011-06-04 | 2012-12-13 | Rochester General Hospital Research Institute | Compositions et procédés associés à la protéine p6 de l'haemophilus influenzae |
| BR112015012351A8 (pt) | 2012-11-29 | 2019-10-01 | Insmed Inc | composição de antibiótico de glicopeptídeo à base de lipídeo estabilizado e uso de um componente lipídico, um componente de antibiótico de glicopeptídeo e um aminoácido ou derivado do mesmo |
| WO2015175939A1 (fr) | 2014-05-15 | 2015-11-19 | Insmed Incorporated | Méthodes de traitement d'infections pulmonaires mycobactériennes non-tuberculeuses |
| JP7460534B2 (ja) | 2018-03-30 | 2024-04-02 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| EP4103725A4 (fr) * | 2020-02-14 | 2024-03-27 | Asklepios Biopharmaceutical Inc | Procédé de traitement d'une toxicité associée à une thérapie génique avec des antibiotiques |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US53264A (en) * | 1866-03-20 | Improved ditching-machine | ||
| YU43116B (en) | 1979-04-02 | 1989-04-30 | Pliva Pharm & Chem Works | Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox |
| YU43006B (en) | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| RU2066324C1 (ru) | 1987-07-09 | 1996-09-10 | Пфайзер Инк. | Кристаллический дигидрат азитромицина и способ его получения |
| WO1989002271A1 (fr) | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycine et derives utilises comme agents anti-protozoaires |
| YU45590A (sh) | 1990-03-07 | 1992-07-20 | PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. | Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje |
| TW271400B (fr) | 1992-07-30 | 1996-03-01 | Pfizer | |
| WO1994026758A1 (fr) | 1993-05-19 | 1994-11-24 | Pfizer Inc. | Intermediaire s'appliquant a l'azithromycine |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| WO1995030422A1 (fr) | 1994-05-06 | 1995-11-16 | Pfizer Inc. | Formes galeniques a liberation controlee de l'azithromycine |
| HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
-
2002
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Application Discontinuation
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 EP EP02753170A patent/EP1418924A2/fr not_active Withdrawn
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 CA CA002458135A patent/CA2458135A1/fr not_active Abandoned
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/fr not_active Application Discontinuation
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
-
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
-
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-19 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
-
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030148964A1 (en) | 2003-08-07 |
| PL367888A1 (en) | 2005-03-07 |
| BG108537A (bg) | 2005-02-28 |
| KR20040032942A (ko) | 2004-04-17 |
| US6987093B2 (en) | 2006-01-17 |
| TNSN04035A1 (fr) | 2006-06-01 |
| MXPA04001605A (es) | 2004-07-08 |
| EP1418924A2 (fr) | 2004-05-19 |
| HRP20040163A2 (en) | 2005-02-28 |
| US20040023898A1 (en) | 2004-02-05 |
| CZ2004232A3 (cs) | 2005-10-12 |
| BR0211830A (pt) | 2004-09-08 |
| WO2003018031A2 (fr) | 2003-03-06 |
| WO2003018031A3 (fr) | 2003-10-02 |
| AP2004002968A0 (en) | 2004-03-31 |
| HUP0401332A2 (hu) | 2004-11-29 |
| AP1729A (en) | 2007-03-26 |
| MA27059A1 (fr) | 2004-12-20 |
| US7067493B2 (en) | 2006-06-27 |
| YU8804A (sh) | 2006-08-17 |
| CA2458135A1 (fr) | 2003-03-06 |
| US20050250712A1 (en) | 2005-11-10 |
| JP2005501862A (ja) | 2005-01-20 |
| EA200400214A1 (ru) | 2004-06-24 |
| IL159585A0 (en) | 2004-06-01 |
| SK1012004A3 (sk) | 2005-04-01 |
| IS7092A (is) | 2003-12-23 |
| GEP20063812B (en) | 2006-05-10 |
| ECSP044985A (es) | 2004-04-28 |
| OA12845A (en) | 2006-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7067493B2 (en) | Single dose azithromycin | |
| Weightman et al. | Traditional Chinese acupuncture as an antiemetic. | |
| US20060210592A1 (en) | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis | |
| ES2713954T3 (es) | Tratamiento de enfermedades asociadas al uso de antibióticos | |
| JP2010511039A5 (fr) | ||
| Marchi | Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis | |
| Tush et al. | Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection | |
| US20060210483A1 (en) | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections | |
| US20200330487A1 (en) | Prevention and treatment of flu-type viral infections and related complications | |
| Kavi et al. | A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin | |
| Raeburn et al. | Ciprofloxacin therapy in cystic fibrosis | |
| US11090315B1 (en) | Prevention and treatment of flu-type viral infections and related complications | |
| AU2002313574A1 (en) | Single dose azithromycin for treating respiratory infections | |
| Dunlop et al. | THK DANGERS OF ANTIBIOTIC TREATMENT | |
| CN114375200A (zh) | 治疗传染病的药物和方法 | |
| US20030109565A1 (en) | Antipyretic preparation containing xylitol | |
| Gooch III et al. | Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion | |
| Bentley et al. | Lincomycin in the treatment of penicillin-resistant staphylococcal infections in children. | |
| Sataloff et al. | Very high-dose streptomycin labyrinthectomy | |
| JPH0235723B2 (fr) | ||
| WO2023052830A2 (fr) | Prévention et traitement d'infections virales de type grippe et de complications associées | |
| RU2180532C2 (ru) | Способ лечения папилломатоза | |
| PT100729A (pt) | Processo para a preparacao de um medicamento contendo subsalicilato de bismuto para tratamento antimicrobiano | |
| US20060057133A1 (en) | Topical pathogenic-tissue-destroying liquid | |
| DuPont | Overview of clinical experience of pefloxacin in gastrointestinal infections |